Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F. Stella S, et al. Among authors: tirro e. Int J Mol Sci. 2019 May 6;20(9):2226. doi: 10.3390/ijms20092226. Int J Mol Sci. 2019. PMID: 31064152 Free PMC article.
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B. Bellodi C, et al. Among authors: tirro e. J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13. J Clin Invest. 2009. PMID: 19363292 Free PMC article.
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F. Stagno F, et al. Among authors: tirro e. Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. Epub 2009 Apr 29. Leuk Res. 2009. PMID: 19406471 No abstract available.
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Stagno F, Vigneri P, Del Fabro V, Stella S, Restuccia N, Giallongo C, Massimino M, Berretta S, Pennisi MS, Tibullo D, Tirrò E, Buscarino C, Messina A, Di Raimondo F. Stagno F, et al. Among authors: tirro e. Acta Oncol. 2010;49(1):109-10. doi: 10.3109/02841860903302913. Acta Oncol. 2010. PMID: 19842797 No abstract available.
Uncommon long-term survival in a patient with chronic myeloid leukemia.
Stagno F, Vigneri P, Stagno F, Vigneri P, Del Fabro V, Stella S, Berretta S, Massimino M, Tirrò E, Messina A, Di Raimondo F. Stagno F, et al. Among authors: tirro e. Acta Oncol. 2009;48(8):1215-6. doi: 10.3109/02841860903156475. Acta Oncol. 2009. PMID: 19863235 No abstract available.
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P. Massimino M, et al. Among authors: tirro e. Carcinogenesis. 2014 May;35(5):1132-43. doi: 10.1093/carcin/bgu013. Epub 2014 Jan 20. Carcinogenesis. 2014. PMID: 24445143
50 results